

NUCALA (MEPOLIZUMAB) INJECTION ORDERS

P: 877.365.5566 | **F:** 855.889.2946

PATIENT	INFORMATION:	Fax completed form, insura	nce information, and clinic	al documentation to 855.889.2946	
				Phone:	
		☐ Continuing Therapy	Next Treatment Dat	te:	
MEDICAL	INFORMATION				
Diagnosis:	☐ Severe persistent as	thma, uncomplicated (IC	D-10 code: J45.50)		
	☐ Severe persistent asthma with acute exacerbation (ICD-10 code: J45.51)				
	\square Eosinophilic Granulomatosis with Polyangiitis (EGPA) (ICD-10 code: M30.1)				
	\square Hypereosinophilic Syndrome (HES) (ICD-10 code: D72.11)				
	☐ Eosinophilic Asthma (ICD-10 code: J82.83)				
	☐ Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (ICD-10 code:)				
	Other:	(ICD-10	code:	_)	
Patient Weight: lbs. Allergies:					
THERAPY	ORDER				
Severe Ast	hma or CRSwNP Dosir	ıg:			
□Nu	cala 100mg subcutane	ously every 4 weeks x 1	year		
= 0 D 4					
EGPA or H					
☐ Nucala 300mg subcutaneously every 4 weeks x 1 year					
		_		7	
Lab Orders	.	Frequency:	☐ Every infusion L	Other:	
Required labs to be drawn by: Infusion Center Referring Provider					
required is	ibs to be arawn by.		creming i rovider		
Other orde	rs:				
0 0.101 0.101	. •				
PROVIDE	RINFORMATION				
				orization and specialty pharmacy designated	
		mpanies, and to select the preferred site of Signature:		Date:	
Provider NP	l:Phone	: Fax:	Contact	Person:	
Provider Name: Signature: Date: Provider NPI: Phone: Fax: Contact Person: Opt out of Paragon selecting site of care (if checked, please list site of care):					
PREFERR	ED LOCATION				
				0,70	
City:	State	e: View	our locations here:		



COMPREHENSIVE SUPPORT FOR NUCALA (MEPOLIZUMAB) THERAPY

PATIENT INFORMATION:					
Patient Name: DOB:					
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE AP	PROVAL				
☐ Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)					
☐ Include patient demographic information and insurance information					
☐ Include patient's medication list					
☐ Supporting clinical notes to include any past tried and/or failed therapies, into benefits, or contraindications to conventional therapy	lerance,				
☐ Please indicate any tried and failed therapies (if applicable): ☐ Corticosteroids					
☐ Long acting beta 2 agonist					
☐ Long acting muscarinic antagonist					
☐ Immunosuppressants (EGPA)					
 □ Does the patient have a history of 2 exacerbations requiring a course of oral systemic corticosteroids, hospitalization or an emergency room visit within 12-month period? □ Yes □ No 	=				
☐ Does the patient have an ACQ score consistently greater than 1.5 or ACT so consistently less than 120 (asthma)? ☐ Yes ☐ No	core				
☐ Include labs and/or test results to support diagnosis					
Does patient have a baseline peripheral blood eosinophil level of ≥ 150 cells within the past 6 weeks (asthma & EGPA) or ≥ 1000 cells/mcL within 4 we (HES)? ☐ Yes ☐ No (attach CBC)	-				
FEV1 score (if applicable):					
☐ Is the patient or caregiver <u>able</u> to administer Nucala for self-administration? ☐ Yes ☐ No If no, please state reason:					
Other medical necessity:					

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance